La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Pharvaris a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Pharvaris..

Pharvaris (NASDAQ:PHVS) Azioni, Catena delle Opzioni

Pharvaris

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .

Pharvaris NV

Biotech

News

Health Care

General

ENSC

Ensysce Biosciences Has Received Notice From The Nasdaq Stock Market That The Company May Continue Its Listing On The Nasdaq Capital Market Tier With An Extension To November 14

Global Indemnity Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBLI#NYSE">GBLI</a>) reported quarterly earnings of $0.95 per share which beat the analyst consensus estimate of $0.57 by 66.67 percent. This is a 69.64 percent increase over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $111.761 million which missed the analyst consensus estimate of $123.000 million by 9.14 percent. This is a 11.34 percent decrease over sales of $126.061 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

GBLI

Global Indemnity Group Q3 2024 Adj. EPS $0.95 Beats $0.57 Estimate, Sales $111.761M Miss $123.000M Estimate

Nortech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) reported quarterly losses of $(0.27) per share. This is a 164.29 percent decrease over earnings of $0.42 per share from the same period last year. The company reported $31.41 million in sales this quarter. This is a 5.88 percent decrease over sales of $33.37 million the same period last year.

NSYS

Nortech Systems Q3 EPS $(0.27) Down From $0.42 YoY, Sales $31.41M Down From $33.37M YoY

MEDIROM Healthcare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) announced a business alliance with SBC Medical Group Holdings Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBC#NASDAQ">SBC</a>) a global owner, operator and provider of management services and products to cosmetic treatment centers.
Our two leading healthcare service providers have more than 4 million members across their loyalty programs at SBC's "Shonan Beauty Clinic" and MEDIROM's "Re.Ra.Ku wellness salon". In addition to bringing customers enhanced offerings and expertise, the alliance will seek to create compelling, integrated opportunities to harness the power of these loyal customers and reward them when they receive services at SBC Medical and MEDIROM.

MEDIROM Healthcare Technologies And SBC Medical Group Holdings Announce Business Alliance, Bringing Customers Enhanced Offerings And Expertise, The Alliance Will Seek To Create Compelling, Integrated Opportunities To Harness The Power Of These Loyal Customers And Reward Them When They Receive Services At SBC Medical And MEDIROM

LakeShore Biopharma Initiates Biologics License Application Of PIKA Rabies Vaccine To The Drug Regulatory Authority Of Pakistan

XELA

On November 6, 2024, The Nasdaq Stock Market Notified Exela Technologies That The Nasdaq Hearings Panel Has Determined To Delist The Company's Common Stock And That Trading Of The Company's Securities Will Be Suspended At The Open Of Trading On November 8-Filing

OTR Global downgrades Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from Mixed to Negative.

Downgrades

Analyst Ratings

PANW

OTR Global Downgrades Palo Alto Networks to Negative

Schwab Asset Management&#xAE;, the asset management arm of The Charles Schwab Corporation, today announced the launch of the Schwab Mortgage-Backed Securities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBS#NYSE">SMBS</a>). The first day of trading is expected to be on or about November 19.
With an expense ratio of 0.03%, the Schwab Mortgage-Backed Securities ETF is priced in line with the lowest-priced peer ETFs based on the U.S. Mortgage Lipper category1. The ETF will provide simple access to investment-grade mortgage-backed securities issued and/or guaranteed by U.S. government agencies. It is designed to serve as part of a diversified portfolio.

ETFs

SCHW

SMBS

Schwab Asset Management To Launch The Schwab Mortgage-Backed Securities ETF "SMBS" On Or About November 19

Buybacks

STGW

Stagwell Reveals $125M Increase In Stock Repurchase Program

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Hold.

Reiteration

GILD

Needham Reiterates Hold on Gilead Sciences

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587386a45064ed0001b4b61b/lauren-lieberman">Barclays analyst Lauren Lieberman</a> downgraded the rating for Coty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) from Equal-Weight to Underweight and lowered the price target from $8 to $7. Coty shares closed at $7.43 on Wednesday. <a href="https://www.benzinga.com/quote/COTY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Sean Milligan downgraded Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) from Hold to Underperform and cut the price target from $93 to $61. Enphase Energy shares closed at $74.81 on Wednesday. <a href="https://www.benzinga.com/quote/ENPH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Laura Champine downgraded the rating for Crocs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) from Buy to Hold and lowered the price target from $150 to $110. Crocs shares closed at $102.74 on Wednesday. <a href="https://www.benzinga.com/quote/CROX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Toni Sacconaghi downgraded Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) from Outperform to Market Perform and announced a price target of $11. Ford shares closed at $11.19 on Wednesday. <a href="https://www.benzinga.com/quote/F/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59009b5a0bd9910001e5f2aa/bradley-thomas">Keybanc analyst Bradley Thomas </a>downgraded the rating for Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) from Overweight to Sector Weight. Dollar Tree shares closed at $62.41 on Wednesday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Ford stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-1024x586.png" alt="" class="wp-image-635158" style="width:545px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07080339/image-76.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

COTY

CROX

DLTR

ENPH

This Ford Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

NKT Photonics to deliver three innovative prototype optical subsystems to IonQ in 2025
NKT Photonics' advanced laser systems will be integrated into IonQ's upcoming data center-ready quantum systems
IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>), a leader in the quantum computing industry, announced today a partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nktphotonics.com%2F&amp;esheet=54148577&amp;newsitemid=20241107761716&amp;lan=en-US&amp;anchor=NKT+Photonics&amp;index=1&amp;md5=e2aeed3e06c83873b1e9149d1f342cf4">NKT Photonics</a>, a subsidiary of Hamamatsu Photonics, to procure next-generation laser systems for IonQ's trapped-ion quantum computers and networking equipment. The partnership involves NKT Photonics developing and delivering three prototype optical subsystems to IonQ in 2025, designed to support the commercialization of IonQ's data center-ready quantum computers – such as IonQ Tempo and future barium-based systems.

IONQ

IonQ Announces Partnership With NKT Photonics For Next-Generation Laser Systems To Power Future Quantum Computers

Guidance

Stagwell Reaffirms FY24 Guidance For Organic Net Revenue Growth Of 5% To 7%; Adjusted EBITDA Of $400M - $450M; Free Cash Flow Conversion Of ~50%

Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 65.35 percent increase over losses of $(1.27) per share from the same period last year.

LPCN

Lipocine Q3 EPS $(0.44) Beats $(0.48) Estimate

FSTR

L.B. Foster Sees FY 2024 Net Sales $530M-$540M Vs $540.92M Est.

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $207 price target.

Price Target

JAZZ

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $207 Price Target

COEP

Coeptis Therapeutics Announces Phase 1 Data On DVX201 For COVID-19 Treatment Has Been Accepted For Publication in 'Molecular Therapy Methods and Clinical Development'

WK Kellogg Raises FY24 Adj. EBITDA Guidance; Sees FY24 Adj. EBITDA Growth Of 5%-6%

Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.72) by 11.11 percent. This is a 25.58 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $354.62 million which beat the analyst consensus estimate of $225.00 thousand by 157.51K percent. This is a 110.90K percent increase over sales of $319.47 thousand the same period last year.

APRE

Aprea Therapeutics Q3 EPS $(0.64) Beats $(0.72) Estimate, Sales $354.62M Beat $225.00K Estimate

Endeavor Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDR#NYSE">EDR</a>) reported quarterly sales of $2.03 billion which beat the analyst consensus estimate of $1.56 billion by 30.29 percent. This is a 51.12 percent increase over sales of $1.34 billion the same period last year.

Endeavor Q3 EPS From Cont. Ops $(0.44), Down From $(0.24) Last Year, Sales $2.03B, Up From $1.22B Prior Year

Pharvaris (PHVS) has released an update. Pharvaris, a Dutch biopharmaceutical company, has executed the second amendment to its License Agreement w...

Pharvaris Refines License Terms with BRAIN Biotech

Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris (PHVS – Research Report) today and set a price target of $34.00. The compa...

Morgan Stanley Keeps Their Buy Rating on Pharvaris (PHVS)

Pharvaris (PHVS) has released an update. Morgan Conn, Ph.D., the Chief Business Officer of Pharvaris N.V., has voluntarily resigned as of October 4...

Pharvaris CBO Resigns, Team Absorbs Duties

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pharvaris (PHVS – Research Report), Silence Therap...

Analysts Conflicted on These Healthcare Names: Pharvaris (PHVS), Silence Therapeutics (SLN) and Stevanato Group (STVN)

Pharvaris (PHVS) Gets a Buy from Morgan Stanley

In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on Pharvaris (PHVS – Research Report), with a price target of $42.0...

Oppenheimer Sticks to Their Buy Rating for Pharvaris (PHVS)

Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)

In a report released today, Maxwell Skor from Morgan Stanley maintained a Buy rating on Pharvaris (PHVS – Research Report), with a price target of ...

Pharvaris (PHVS) Receives a Buy from Morgan Stanley

Pharvaris (PHVS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Joseph Schwartz from L...

Pharvaris's Promising Developments in HAE Treatment Drive Buy Rating

PHVS

STVN

Press Releases

Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update

Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

Pharvaris Presents Data at the Bradykinin Symposium 2024

Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024

Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

Pharvaris to Host Virtual Investor Event on October 23, 2024

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

Axonis Therapeutics Announces $115 Million Series A Financing

AKRO

APLS

AUPH

CINC

CMPI

HRMY

RYZB

TPTX

Jones Trading

Oppenheimer

Wedbush

Morgan Stanley

JMP Securities

Comments

Pharvaris

Pharvaris (PHVS) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO